Cannabis Law Report

JUNE 7, 2021

IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.

Clinical Trials 105

Clinical Trials Patients THC Safety 105

FloridaMarijuana.net

AUGUST 16, 2018

They estimate that the number of people aged 65 years and older is expected to increase from 35 million in 2000 to 71 million in 2030. million in 2030. Globally, the number of older adults (aged 65 years and older) is projected to increase even more dramatically — more than doubling from 420 million in 2000 to 973 million in 2030.

Clinical Trials 184

Clinical Trials Marijuana Patients Pharmaceutical 184

Cannabis Law Report

FEBRUARY 3, 2022

DUBLIN–(BUSINESS WIRE)–The “Global Cannabis Market- Market Size & Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering. The global cannabis market in the COVID-19 period has been estimated to value USD 25,650.4 million by 2030 at a CAGR of 23.9%, 2021-2030.

Indica 52

Indica Oil Legalization Research and Development 52